Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
115.13
0.00 (0.00%)
Jun 24, 2025, 8:00 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.62B in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
53.22B
Revenue Growth
+11.50%
P/S Ratio
4.42
Revenue / Employee
701.37K
Employees
75,883
Market Cap
235.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Novartis AG News
- 16 hours ago - Final Trades: Novartis, Sixth Street, Amazon and the IYF - CNBC
- 17 hours ago - Novartis in deal with ProFound for cardiovascular disease therapies - Seeking Alpha
- 22 hours ago - ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease - GlobeNewsWire
- 1 day ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 1 day ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 1 day ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily
- 1 day ago - Novartis: A SWAN Worth Owning - Seeking Alpha
- 2 days ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire